Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Giant Biogene Holding Co's cash flow for dividends for the
six
months ended in Dec. 2025 was HK$-1,400 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Giant Biogene Holding Co's quarterly payment of dividends
declined
from Dec. 2024 (HK$-985 Mil) to Jun. 2025 (HK$0 Mil) but then
increased
from Jun. 2025 (HK$0 Mil) to Dec. 2025 (HK$-1,400 Mil).
Giant Biogene Holding Co's annual payment of dividends
increased
from Dec. 2023 (HK$0 Mil) to Dec. 2024 (HK$-985 Mil) and
increased
from Dec. 2024 (HK$-985 Mil) to Dec. 2025 (HK$-1,387 Mil).
Giant Biogene Holding Co Cash Flow for Dividends Related Terms
Giant Biogene Holding Co Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for Giant Biogene Holding Co's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co Cash Flow for Dividends Chart
Giant Biogene Holding Co Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of HK$0 Mil mean?
Giant Biogene Holding Co (HKSE:02367) has a Cash Flow for Dividends of HK$0 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Giant Biogene Holding Co and its competitors.
Is Giant Biogene Holding Co's Cash Flow for Dividends too high?
Giant Biogene Holding Co's current Cash Flow for Dividends is HK$0 Mil. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's Cash Flow for Dividends compare to PG and CL?
Giant Biogene Holding Co's Cash Flow for Dividends of HK$0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Consumer Packaged Goods company?
A good Cash Flow for Dividends depends on the Consumer Packaged Goods industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Giant Biogene Holding Co and its competitors. Giant Biogene Holding Co's current Cash Flow for Dividends is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.00, compared to a current price of HK$24.26 — trading 64.3% below its estimated fair value. The current Cash Flow for Dividends is HK$0 Mil. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current Cash Flow for Dividends is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.26 is trading 64.3% below its estimated GF Value™ of HK$68.00.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
Cash Flow for Dividends: HK$0 Mil
GF Value™: HK$68.00 vs. price of HK$24.26 (64.3% below fair value)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
